Literature DB >> 2769073

Relationship of decreased hepatic lipase activity and lipoprotein abnormalities to essential fatty acid deficiency in cystic fibrosis patients.

E Lévy1, G Lepage, M Bendayan, N Ronco, L Thibault, N Galéano, L Smith, C C Roy.   

Abstract

Polyunsaturated fatty acids are known to affect plasma lipids and lipoproteins but there is no information on the effect of essential fatty acid (EFA) deficiency on lipoprotein composition. The purpose of this study was to characterize lipoproteins from 17 cystic fibrosis (CF) patients in relationship to their EFA status (eicosatrienoic/arachidonic acid ratio) and compare them with those of 10 healthy siblings (SIB) and of 10 unrelated controls. In 7 EFA-deficient (EFAD) and 10 EFA-sufficient (EFAS) patients, hypocholesterolemia was associated with a decrease of HDL-cholesterol and of LDL-cholesterol which was more marked in the EFAD group. Similarly, although triglyceride enrichment of VLDL, LDL, HDL2, and HDL3 with a concomitant reduction of cholesteryl esters from all particles except HDL2 was observed in both CF groups, it was more sizable in the EFAD patients. These changes led to an increase in the particle size of VLDL, LDL, and HDL2 whereas the distribution of HDL3 was skewed to smaller particles. Alterations in the apoprotein composition of particles were greater in EFAD than in EFAS. A decrease of total postheparin lipolytic activity was observed in the two groups of CF patients as well as in siblings. It was entirely accounted for by hepatic lipase (mumol FFA/ml per h) which was more severely diminished in EFAD (2.8 +/- 0.6) than in EFAS (4.4 +/- 0.7) and SIB (5.1 +/- 0.5). Although the two groups of CF children differed in terms of growth, severity of malabsorption, and vitamin E status, these data suggest that disturbance of lipoprotein concentration, composition, size, and metabolism (hepatic lipase) may be in part related to EFA deficiency. Further studies are necessary to explore the effect of EFA deficiency on hepatic lipase activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2769073

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors.

Authors:  Sophia Morel; Jade Leahy; Maryse Fournier; Benoit Lamarche; Carole Garofalo; Guy Grimard; Floriane Poulain; Edgard Delvin; Caroline Laverdière; Maja Krajinovic; Simon Drouin; Daniel Sinnett; Valérie Marcil; Emile Levy
Journal:  J Lipid Res       Date:  2017-03-08       Impact factor: 5.922

Review 2.  Cystic fibrosis-related oxidative stress and intestinal lipid disorders.

Authors:  Marie-Laure Kleme; Emile Levy
Journal:  Antioxid Redox Signal       Date:  2015-01-22       Impact factor: 8.401

3.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

4.  Serum fatty acid profiles in cystic fibrosis patients and their parents.

Authors:  A B Christophe; W J Warwick; R T Holman
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

5.  Combined effects of EFA deficiency and tumor necrosis factor-alpha on circulating lipoproteins in rats.

Authors:  Emile Levy; Edgard Delvin; Noel Peretti; Guylaine Bouchard; Ernest Seidman
Journal:  Lipids       Date:  2003-06       Impact factor: 1.880

6.  CFTR Deletion Confers Mitochondrial Dysfunction and Disrupts Lipid Homeostasis in Intestinal Epithelial Cells.

Authors:  Marie L Kleme; Alain Sané; Carole Garofalo; Ernest Seidman; Emmanuelle Brochiero; Yves Berthiaume; Emile Levy
Journal:  Nutrients       Date:  2018-06-27       Impact factor: 5.717

7.  Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients.

Authors:  Daniel C Ma; Alexander J Yoon; Kym F Faull; Robert Desharnais; Edith T Zemanick; Edith Porter
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

8.  Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?

Authors:  Emina Halilbasic; Elisabeth Fuerst; Denise Heiden; Lukasz Japtok; Susanne C Diesner; Michael Trauner; Askin Kulu; Peter Jaksch; Konrad Hoetzenecker; Burkhard Kleuser; Lili Kazemi-Shirazi; Eva Untersmayr
Journal:  Nutrients       Date:  2020-03-14       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.